Safety and Efficacy of VDPHL01 in Males and Females With AGA

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

August 28, 2026

Conditions

Androgenetic AlopeciaAGAMale Pattern Baldness

Interventions

DRUG

VDPHL01

VDPHL01 Extended Release (ER) Tablet

Trial Locations (4)

04, New Albany

02, South Jordan

01, San Diego

03, Hackensack

All Listed Sponsors

lead

Veradermics, Inc.

INDUSTRY

NCT06527365 - Safety and Efficacy of VDPHL01 in Males and Females With AGA | Biotech Hunter | Biotech Hunter